Newcastle University

Roles and Responsibilities

Computing group co-ordinator
Chromatography Room
POG IT and Networks
Building management group
Nitrogen gas supplies for LCMS etc

Qualifications

M.I. Biol North East Surrey College of Technology 1975

Previous Positions

Drug Development Section, Institute of Cancer Research, Sutton, Surrey (Senior Research Officer). 1972-1989

Memberships

BACR
EORTC Pharmacokinetics and Molecular Mechanism (PAMM) Group

Research Interests

Antimetabolites especially antifolates. Nucleoside and nucleotide metabolism

Other Expertise

HPLC
LCMS
General chromatographic techniques and method development
Nucleoside/nucleotide analysis

• Coulthard SA, Redfern CPF, Vikingsson S, Lindqvist-Appell M, Skoglund K, Jakobsen-Falk I, Hall AG, Taylor GA, Hogarth LA. Increased Sensitivity to Thiopurines in Methylthioadenosine Phosphorylase-Deleted Cancers. Molecular Cancer Therapeutics 2011, 10(3), 495-504.
• Pridgeon SW, Heer R, Taylor GA, Newell DR, O'Toole K, Robinson M, Xu YZ, Karran P, Boddy AV. Thiothymidine combined with UVA as a potential novel therapy for bladder cancer. British Journal of Cancer 2011, 104(12), 1869-1876.
• Wells, P., Aboagye, E., Gunn, R., Osman, S., Boddy, A. V., Taylor, G. A., Rafi, I., Hughes, A. N., Calvert, A. H., Price, P., Newell, D. R. 2-[¹¹C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. Journal of the National Cancer Institute 2003, 95(9), 675-682.
• Taylor RW, Taylor GA, Durham SE, Turnbull DM. The determination of complete human mitochondrial DNA sequences in single cells: implications for the study of somatic mitochondrial DNA point mutations. Nucleic Acids Research 2001, 29(15), e74.
• Jodrell, D., Bowman, A., Rye, R., Byrne, B., Boddy, A. V., Rafi, I., Taylor, G., Johnston, A., Clendeninn, N. A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq® (nolatrexed dihydrochloride) given by 10-day oral administration. British Journal of Cancer 1999, 79(5/6), 915-920.
• Taylor GA, Estlin EJ, Pinkerton CR, Gowing R, Lashford L, Morland B, Lewis IJ, Newell DR, Boddy AV, Johnston A, Pearson ADJ. Deoxyuridine plasma levels during the phase I study of nolatrexed in children with advanced cancer. Annals of Oncology 1998, 9(Supplement 2), 161 - A618.
• Rafi, I., Boddy, A. V., Calvete, J., Taylor, G. A., Newell, D. R., Bailey, N. P., Lind, M., Green, M., Hines, J., Johnstone, A., Clendeninn, N., Calvert, A. H. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given prolonged administration in patients with solid tumors. Journal of Clinical Oncology 1998, 16(3), 1131-1141.
• Rafi, I., Taylor, G. A., Calvete, J. A., Boddy, A. V., Balmanno, K., Bailey, N., Lind, M., Calvert, A. H., Webber, S., Jackson, R. C., Johnston, A., Clendeninn, N., Newell, D. R. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridplthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion. Clinical Cancer Research 1995, 1(11), 1275-1284.